Abstract 61PD
Aim/Background
Triple-negative breast cancer (TNBC) is a highly diverse group of cancers, and subypting is necessary to better identify molecular-based therapies. The purpose of this study was to investigate the role of Ki67 in further classification of TNBC into subtypes with different prognosis, and whether these subtypes could benefit from carboplatin.
Methods
From January 2004 to December 2012, 363 continuous TNBC patients were identified from the institutional clinical database. The Log-rank test were used to assess impact of different factors on disease-free survival (DFS) and overall survival (OS). A multivariate Cox proportional hazards regression model was performed to analyze the independent prognostic factors. Interaction between use of carboplatin and Ki67 was graphically evaluated by use of Sub population Treatment Effect Pattern Plot (STEPP) methodology.
Results
High Ki67 index (defined as >40%) was more common in younger age (P < 0.001), and was associated with worse differentiation (p < 0.001).High Ki67 patients received more chemotherapy than the low Ki67 group (p =0.007). After a median follow-up time of 34 months (5.2-120.0 months), 62 patients (17.1%) had relapses and 33 patients (9.1%) died of breast cancer. In univariate analysis, high Ki67 index as well as larger tumor size and lymph node involvement was associated with shorter DFS and OS. In multivariate analysis, Ki67 is an independent prognostic factor for DFS (Risk Ratio, RR: 2.835, 95% confidence interval, 95% CI: 1.586-5.068, P < 0.001) and OS (RR: 3.180, 95% CI: 1.488-6.793, P = 0.003). When analyzing the 3-year DFS by Ki67 distribution, STEPP analysis showed a possible beneficial effect of carboplatin in patients with high Ki67 index.
Conclusions
TNBC is probably a heterogeneous disease with different characteristics and prognosis, and may be further stratified according to the Ki67 expression levels. Patients in the high Ki67 group seem to benefit from treatment with carboplatin, but this needs to be further verified.
Clinical trial identification
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
Quality of life in TSU-68 study: Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline
Presenter: Byeong Seok Sohn
Session: Breast cancer
Resources:
Abstract
Prognosis of multifocal/multicentric breast cancers
Presenter: Delphine Hequet
Session: Breast cancer
Resources:
Abstract
Predictive role of stromal tumor infiltrating lymphocytes (TILs) in patients with metastatic HER2-positive breast cancer (BC) treated with trastuzumab
Presenter: Changhoon Yoo
Session: Breast cancer
Resources:
Abstract
Phase III HannaH study of subcutaneous or intravenous trastuzumab for HER2-positive early breast cancer: Exploratory subgroup analyses of pathological complete response and 3-year event-free survival by body weight and anti-drug antibody status
Presenter: Jin-Seok Ahn
Session: Breast cancer
Resources:
Abstract
Multicenter observational study of fulvestrant 500 mg in postmenopausal Japanese women with ER positive advanced or recurrent breast cancer after prior endocrine treatment (SBCCSG29 study)
Presenter: Kei Kimizuka
Session: Breast cancer
Resources:
Abstract
Invited discussant abstracts 59PD, 60PD, 61PD and 62PD
Presenter: Takayuki Iwamoto
Session: Breast cancer
Invited discussant abstracts 56PD, 57PD and 58PD
Presenter: Masakazu Toi
Session: Breast cancer
Invited discussant abstracts 53O and 55O
Presenter: Rebecca Dent
Session: Breast cancer
Comparison of incidental radiation dose to axilla and internal mammary nodal area by conventional, 3DCRT, and IMRT technique in carcinoma of breast
Presenter: H B Govardhan
Session: Breast cancer
Resources:
Abstract